News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights
Submitted a New Drug Application to the U.S. Food and Drug Administration for the review of tenapanor as a first-in-class therapy to control serum phosphorus in adult patients with chronic kidney disease on dialysis   Maintains strong balance sheet with $204.8 million in cash, cash equivalents and
View HTML
Toggle Summary Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor
A New Drug Application for the Review of Tenapanor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis has Been Submitted to the FDA FREMONT, Calif. , Aug. 3, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on
View HTML
Toggle Summary Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Application is Supported by Three Positive Phase 3 Clinical Trials for Tenapanor for Hyperphosphatemia, a Condition which affects Approximately 85% of CKD Patients on Dialysis FREMONT, Calif. , June 30, 2020 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on
View HTML
Toggle Summary Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis
Foundational use of tenapanor as monotherapy or with sevelamer enabled up to 47.4% of patients to achieve normal serum phosphorus levels (
View HTML
Toggle Summary Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FREMONT, Calif. , June 9, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that on June 8, 2020, the
View HTML
Toggle Summary Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer
FREMONT, Calif. , June 8, 2020 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the appointment of Justin Renz to
View HTML
Toggle Summary Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference
FREMONT, Calif. , May 26, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Mike Raab , president and
View HTML
Toggle Summary Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FREMONT, Calif. , May 21, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that on  May 18, 2020 , the
View HTML
Toggle Summary Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer
FREMONT, Calif. , May 18, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the appointment of Susan Rodriguez
View HTML
Toggle Summary Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights
Company maintains strong balance sheet with $223.2 million in cash, cash equivalents and short-term investments FREMONT, Calif. , May 7, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve
View HTML